Autoimmune Disease Clinical Trials

11 recruiting

Autoimmune Disease Trials at a Glance

107 actively recruiting trials for autoimmune disease are listed on ClinicalTrialsFinder across 6 cities in 25 countries. The largest study group is Not Applicable with 24 trials, with the heaviest enrollment activity in Beijing, Hangzhou, and Wuhan. Lead sponsors running autoimmune disease studies include The Children's Hospital of Zhejiang University School of Medicine, Tongji Hospital, and Assistance Publique - Hôpitaux de Paris.

Browse autoimmune disease trials by phase

Treatments under study

About Autoimmune Disease Clinical Trials

Looking for clinical trials for Autoimmune Disease? There are currently 11 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Autoimmune Disease trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Autoimmune Disease clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 107 trials

Recruiting

Deciphering the Genetic Architecture of Autoimmune Diseases

Autoimmune Diseases
National Human Genome Research Institute (NHGRI)300 enrolled2 locationsNCT06948110
Recruiting
Phase 1

A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases

Refractory Autoimmune Diseases
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company125 enrolled28 locationsNCT07115745
Recruiting

The RheumSafer Study: Improving Medication Appropriateness in People With Rheumatic Conditions

VasculitisSystemic Lupus Erthematosus (SLE)Rheumatic Diseases+3 more
McGill University Health Centre/Research Institute of the McGill University Health Centre100 enrolled1 locationNCT07278609
Recruiting
Not Applicable

Single-cell Immune Response to Controlled Gluten Ingestion in Pediatric Celiac Disease

Celiac DiseaseAutoimmune DiseasesGluten Sensitivity
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud51 enrolled1 locationNCT07362654
Recruiting
Not Applicable

CAR-T Therapy for Refractory Autoimmune Diseases

Autoimmune Diseases
LiangZou20 enrolled1 locationNCT07059169
Recruiting
Phase 1Phase 2

Autoimmune Disease Treatment With Mesenchymal Stem Cells (MSCs) and CAR-T Cells

Autoimmune Diseases
Shenzhen Geno-Immune Medical Institute30 enrolled1 locationNCT06435897
Recruiting
Phase 1

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035 in Healthy Participants and in Adults With Autoimmune Dermatological Diseases

Healthy ParticipantsHealthy VolunteersAutoimmune Diseases+1 more
BeiGene211 enrolled13 locationsNCT06342713
Recruiting
Phase 1

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

Malignant Solid NeoplasmHematopoietic and Lymphoid Cell NeoplasmRheumatoid Arthritis+11 more
National Cancer Institute (NCI)300 enrolled52 locationsNCT03816345
Recruiting
Phase 2

Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

Autoimmune DiseaseProteinuriaGlomerular Disease+2 more
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)30 enrolled2 locationsNCT00977977
Recruiting

The Mycophenolate Pregnancy Registry

Heart Transplantation, Kidney Transplantation, Liver Transplantation, Autoimmune Diseases
Genentech, Inc.500 enrolled1 locationNCT01733082
Recruiting
Not Applicable

Testimonials and Navigation in Rheumatology

Autoimmune DiseasesRheumatologic Disease
University of Alabama at Birmingham1,170 enrolled3 locationsNCT06469788
Recruiting

Natural History of Bronchiectasis

Cystic FibrosisBronchiectasisAutoimmune Disease+1 more
National Heart, Lung, and Blood Institute (NHLBI)900 enrolled1 locationNCT00943514
Recruiting
Not Applicable

Treatment Strategies for IgG4-RD Patients With Superficial Organ Involvement

Autoimmune Diseases
Peking Union Medical College Hospital60 enrolled1 locationNCT05789030
Recruiting
Early Phase 1

Allogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune Disease

IgA Nephropathy (IgAN)Autoimmune DiseasesSystemic Sclerosis (SSc)+3 more
The Children's Hospital of Zhejiang University School of Medicine15 enrolled1 locationNCT07507201
Recruiting
Phase 1

A Study of Safety, Tolerability, PK, and PD of Subcutaneous GenSci136 in Healthy Adults.

Autoimmune Disease
Changchun GeneScience Pharmaceutical Co., Ltd.48 enrolled1 locationNCT07366866
Recruiting
Early Phase 1

A Study of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Patients With Refractory Autoimmune Diseases

Autoimmune Diseases
Ruijin Hospital66 enrolled3 locationsNCT06747156
Recruiting
Early Phase 1

A Clinical Study of AFN50 in the Treatment of Autoimmune Diseases

Relapsed/Refractory Autoimmune Diseases
Beijing Boren Hospital18 enrolled1 locationNCT07448298
Recruiting
Phase 1Phase 2

Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Autoimmune Diseases

Autoimmune Diseases
Beijing GoBroad Hospital18 enrolled1 locationNCT06688799
Recruiting
Not Applicable

Exploratory Clinical Study on the Safety of STR-P004

Autoimmune Diseases
Beijing GoBroad Hospital39 enrolled1 locationNCT07143617
Recruiting
Early Phase 1

Clinical Study of AFN50 Injection in the Autoimmune Diseases

Autoimmune Diseases
AlphaNa Bioscience Company Limited18 enrolled1 locationNCT07408336